Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Neurobiol Dis. Author manuscript; available in PMC 2011 March 1.
Published in final edited form as:
PMCID: PMC2824012


Morris H. Scantlebury, M. D.,1,* Aristea S. Galanopoulou, M. D. Ph. D.,1,2,* Lenka Chudomelova, M.D.,1 Emmanuel Raffo, M. D. Ph. D.,1 David Betancourth,1,4 and Solomon L. Moshé, M. D.1,2,3


Infantile spasms are characterized by age-specific expression of epileptic spasms, hypsarrhythmia and often result in significant cognitive impairment. Other epilepsies or autism often ensue especially in symptomatic IS (SIS). Cortical or subcortical damage, including white matter, have been implicated in the pathogenesis of SIS. To generate a model of SIS, we recreated this pathology by injecting rats with lipopolysaccharide and doxorubicin intracerebrally at postnatal day (P) 3 and with p-chlorophenylalanine intraperitoneally at P5. Spasms occurred between P4–13 and were associated with ictal EEG correlates, interictal EEG abnormalities and neurodevelopmental decline. After P9 other seizures, deficits in learning and memory, and autistic-like behaviors (indifference to other rats, increased grooming) were observed. Adrenocorticotropic hormone (ACTH) did not affect spasms. Vigabatrin transiently suppressed spasms at P5. This new model of SIS will be useful to study the neurobiology and treatment of SIS, including those that are refractory to ACTH.

Keywords: Infantile spasms, West syndrome, autism, animal model, epilepsy, lipopolysaccharide, doxorubicin, p-chlorophenylalanine, neonatal rat


The infantile spasms (IS) syndrome is an age-related epileptic disorder characterized by spasms and hypsarrthythmia, described as high amplitude multifocal epileptiform discharges on a disorganized background(Hrachovy and Frost, 2003). Ictal correlates include the electrodecremental response but can be variable(Kellaway et al., 1979). The emergence of the spasms is often associated with developmental decline that may improve if spasms are treated effectively (Caplan et al., 2002; Goh et al., 2005). Many patients with IS eventually develop other intractable epilepsy syndromes (Rantala and Putkonen, 1999), mental retardation(Riikonen, 1982; Riikonen and Amnell, 1981)and autistic features(Rantala and Putkonen, 1999; Riikonen and Amnell, 1981) leading to lifelong debilitation. Under the current International League Against Epilepsy classification, IS are classified into symptomatic, cryptogenic and idiopathic (Watanabe, 1998). Symptomatic IS (SIS) result from pre-existing brain disorders, often multifocal pathology, and comprise the largest proportion of cases (Hrachovy and Frost, 2003; Watanabe, 1998). Multiple etiologies have been described, often as a combination of additive insults (Watanabe, 1998). In cryptogenic IS, a central nervous system dysfunction is suspected but remains unidentified8. In idiopathic cases the cause is suspected to be genetic.

IS are refractory to most conventional antiepileptic drugs. The recommended first line therapies are adrenocorticotropic hormone (ACTH) and, in patients with IS due to tuberous sclerosis, vigabatrin. ACTH and vigabatrin are not always effective and may have potentially severe side effects(Mackay et al., 2004). The prognosis is better when treatments are effective in controlling IS and even patients with SIS may not regress and continue to acquire developmental milestones at a rate determined by the underlying etiology(Caplan et al., 2002; Goh et al., 2005; Primec et al., 2006). For this purpose, it is crucial to develop successful animal models of SIS to study mechanisms and design more safe and effective treatments. Here we describe an animal model of SIS that satisfies many of the criteria for a successful model of the IS syndrome(Stafstrom et al., 2006). This model was developed based on evidence that structural or functional abnormalities in cortical or subcortical structures or their connections may be necessary to produce IS(Lado and Moshe, 2002). Doxorubicin (DOX) and lipopolysaccharide (LPS) were given intracerebrally at postnatal day (P) 3 and p-chlorophenylalanine (PCPA) was given intraperitoneally (i.p.) at P5. DOX is an antineoplastic agent that, when injected intraventricularly results in diffuse brain damage involving the forebrain and brainstem based on previous reports in adult rats(Siegal et al., 1988). Intracerebral injection of LPS in rat pups activates inflammatory cascades resulting in hypomyelination, white matter rarefaction and necrosis(Pang et al., 2003). PCPA depletes serotonin by inhibiting the enzyme tryptophan hydroxylase, which catalyzes the conversion of tryptophan to serotonin(Rattray et al., 1996). Low serotonin CSF metabolite, 5-hydroxyindoleacetic acid has been observed in patients with IS(Silverstein and Johnston, 1984).

We describe the seizure semiology, EEG features, neurodevelopmental deficits, neuropathology and the response of spasms to ACTH and vigabatrin.



These studies were done in the male offspring of timed pregnant Sprague Dawley rats. Female rats were excluded from this study to avoid gender-related developmental and phenotypic differences. The day of birth was considered as P0 and on P3 the litters were culled to 8 pups. Pups were divided into two experimental groups: 1) Pups that received DOX/LPS/PCPA (DLP pups) 2) handled control pups, which were monitored in parallel to DLP pups. In the subsequent experiments, handled control pups injected with vehicle and naïve pups were combined as no differences in seizure phenotype and neurodevelopment were found. Litters were culled to 8 pups at P3. The pups were kept with the dam throughout the experiments, unless they were monitored. Pups were maintained in a 12hr light/dark cycle with free access to food and water until P20 when they were sacrificed for histological studies. Animal care and use conformed to institutional policy and guidelines of the American Association for the Accreditation of Laboratory Animal Care. All procedures and experiments were performed in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals.

Agents used

After extensive screening studies (supplementary materials) the doses of DOX (5μg/2.5 μl) and LPS (3μg/1.5 μl) were selected that produced the maximal frequency of spasms with minimal mortality. Intracerebral infusions of DOX and LPS were done stereotaxically at P3 under isoflurane anesthesia. Pups were positioned in a stereotaxic frame for neonatal rat surgery (Benchmark Angle One,, St Louis MO). DOX was injected into the right lateral ventricle followed by LPS into the right parietal cortex. The following coordinates were used: DOX: 2.68mm anterior to lamda; 1.1mm lateral to sagittal suture; 3.3 mm deep; LPS: 2.55mm anterior to lambda; 1mm lateral to sagittal suture; 1.7 mm deep. After the injections the skin was closed with Vetbond © and the pups were allowed to recover on a heating pad before returning them to their mother. At P5, pups were injected with PCPA 200 mg/kg i.p.. Sterile saline was used as the vehicle for the three injections.

Behavioral and video-EEG monitoring

The behaviors of the pups were monitored using a video camera for 2hours twice daily from P4 (first post-operative day) until P20. The videos were analyzed for evidence of spasms and other seizures.

Epidural recordings were obtained from 8 DLP and 5 vehicle-injected control pups. P6–9 pups were anesthetized and positioned in the stereotaxic frame as described above and a circuit board (Pinnacle Technology) configured to obtain both EEG and EMG activity was affixed to the skull using Vetbond © and four stainless steel screws. EMG was recorded using two stainless steel subdermal electrodes overlying the trapezius muscles. Pups were individually placed in beakers warmed in a water bath and filled with bedding (31–33 ° C). Video-EEGs were recorded for 2h twice daily (9–11 AM and 3–5 PM) from P7 – 20 except for weekend days (1 daily session only at P7 and P8) using Pinnacle Technology and Stellate systems where appropriate.

Depth EEG recordings were obtained from the entorhinal cortex contralateral to the injection of DOX and LPS in three additional DLP pups that developed flexion spasms and in one non-injected control. In this study, the following coordinates were used: 4.0mm posterior to bregma, 3.3mm left of the sagittal sinus, 6.0mm deep to the skull surface. EEG recordings were obtained during a 45 min session starting from P9 once in two experimental pups and in three consecutive days in the other experimental pup and control pup.

Interictal EEG activities were analyzed in DLP pups and controls in 15 min epochs. To account for state-specific changes in spectral patterns, comparisons were done in the: “awake state” defined as the period the pup was exploring or moving around and the “resting state” when pups were either resting on their side (P7–9) or standing (after P9) without exploratory movements for at least 5 min. Segments with behavioral seizure activity were excluded. To adjust for age, EEGs were separated into three groups: P7–9, P10–13, P14–20. The following parameters were measured: a) discontinuity, defined as intermittent attenuation of the EEG background, at least 5 times lower than the baseline, for more than 10 sec; (b) occurrence of spikes, i.e. sharp waveforms greater than 1.5 times the baseline in amplitude which lasted less than 70msec; (c) Fast Fourier Transform (FFT) analysis was also performed with a 5.2 sec FFT length, 300 sec interval restart without overlapping.

Developmental tests

Pups in all groups underwent a battery of developmental behavioral tests that included the following: 1) Surface righting time (SRT) 2) Negative geotaxis (NG) and 3) Open field activity (OFA) (P3–P20) (Mikulecka and Mares, 2002) 4) Social chamber (P12) (modified from (Bolivar et al., 2007) (Crawley, 2004)) 5) Barnes Maze (P16–19) (modified from(Barnes et al., 1980)).


The brains of 5 DLP pups were obtained at different time points to evaluate, qualitatively, the extent of lesions induced by DLP. The brains were fixed in formalin, sectioned and stained with thionin according to established protocols (see supplementary materials for methods).

Treatment with ACTH and Vigabatrin

Prior to treatment with ACTH the presence of spasms was documented after obtaining a 2h baseline monitoring in the morning and 1h pre-injection baseline in the afternoon. A depot formulation of the tetracosactide, Cosyntropin (Synacthène Retard, Novartis, Switzerland) was injected at a dose of 0.0125mg/kg/day i.p. (P4–P13), which is equivalent to 1.25U/kg/day of ACTH1–39 (n=8 rats). Cosyntropin is the ACTH1–24 fragment of ACTH, which has the same sequence in all known species [( (Uhler and Herbert, 1983)]. Equal volumes of vehicle were injected in 6 control rats. Higher doses (cosyntropin 0.025mg/kg/dose given every 48 hours i.p.) were lethal in 3/3 pups by P11. Pups were injected daily and monitored for 2h following the injection. Monitoring continued twice daily with two-hour sessions till P13 when they were sacrificed. To test the effects of vigabatrin, we used different doses ranging between 20mg/kg and 200mg/kg total daily dose. Because of significant sedation, resulting in poor feeding and early death, most experiments were done with the 20mg/kg i.p. twice daily regimen (n=6 pups), which was better tolerated. Results were compared with vehicle-treated pups (n=9 pups).


Results are expressed as least square means +/− standard errors. The Student's t-test was used to compare the means of two groups of unpaired data; for multiple group comparisons, the one-way or multifactorial analysis of variance (ANOVA) was used with Tukey post hoc comparisons as appropriate. The critical significance level of all tests was p < 0.05.


Spasms, other seizure types and responsiveness to ACTH and Vigabatrin

Flexion, extension or mixed flexion/extension spasms were observed in all DLP pups. Flexion spasms were characterized by the abrupt onset of flexion of the trunk with forward tonic extension of the limbs at the height of the spasm (Figure 1, video 1). The extension spasms were characterized by the sudden hyper-extension of the back with tonic posturing of the limbs (video 2). Spasms first appeared at P4, i.e. prior to the PCPA injection, indicating that PCPA is not necessary for the generation of spasms. However higher PCPA doses were associated with higher frequencies of spasms and therefore PCPA was maintained in our protocol. Spasms typically occurred during the resting state. Spasms were observed only between P4–P13, peaked between P4–P6 and subsequently declined (Figure 2). In controls, rare sporadic abrupt events consisting of brief flexion or extension were observed that resembled spasms were observed, but these were rare, did not appear as forced and were typically in the context of changing their position or stretching.

Figure 1
Flexion spasm in a P9 rat following injections of DOX and LPS at P3 and PCPA at P5. (A) The pup is lying on its side prior to the spasm. (B) The pup raises its head abruptly at the start of the spasm. (C) This is followed by flexion of the trunk, extension ...
Figure 2
Age-specific appearance of spasms in DLP pups. Daily monitoring with two daily 2h-sessions was done starting at P4 till P20 in DLP pups. Spasms appear at P4, peak during P4–7 and disappear after P13.

Other seizures were observed in 67 % in DLP pups starting from P9–20 that included behavioural arrest and wild-running (video 3) seen between P9–12. Tonic seizures, myoclonus with sudden drops, and stage 5 limbic seizures associated with forelimb clonus, rearing and falling seen after P13 (video 4). Myoclonic jerks were very frequent in DLP pups. Less frequent myoclonic jerks were observed in control pups, as previously reported by other investigators(Blumberg et al., 2005). Behaviourally, they were distinguished from spasms in that they were very brief without tonic posturing.

All EEG-monitored DLP pups with spasms had spasms with electrographic correlates. In the epidural EEG recordings, electrodecremental responses (i.e. background attenuation) were noted in 27% of spasms with electrographic correlate (Figure 3). Spike and sharp wave discharges and/or fast rhythmic activities comprised the 73% of electrographic correlates of spasms. However, within the same DLP pups, 51% of captured behavioural spasms either did not have clear EEG correlate (42%) or were associated with artifact (9%). In the depth recordings, electrodecremental pattern time-locked with the spasms in all captured events (figure 4, video 5). In controls, none of the above electrographic events occurred even in the presence of the flexion or extension episodes described earlier.

Figure 3
Examples of ictal EEG patterns in P7–9 DLP pups using epidural recordings. The montage utilized here is bipolar: the upper channel is the right frontal-left parietal derivation and the lower channel is the EMG channel to demonstrate the occurrence ...
Figure 4
Depth EEG recording from the entorhinal cortex during a cluster of 2 spasms in a P9 pup (video 5).

Interictally, frequent spikes or runs of high amplitude spike and slow wave discharges at both the awake and resting state were observed only in P7–13 DLP pups, (Figure 5). Rare isolated spikes of unclear significance occurred in controls perhaps due to immaturity or the prior surgery. Discontinuity of the background activities was seen during the early period of spasms in DLP pups (36% of EEGs, 3/7 DLP P7–9 pups) and not in controls. This difference was significant during the awake state (P<0.01, chi-square). Spectral analysis showed increased alpha only during the resting state, i.e the state when spasms usually occurred in P7–9 DLP pups (data not shown). At P7–13, a shift towards both alpha and theta activities was seen in DLP pups, at either awake or resting state.

Figure 5
Interictal EEG abnormalities in DLP pups.

Electrographic seizure correlates to the other seizures were also identified in DLP pups. Selected examples are shown in Figure 6.

Figure 6
Ictal patterns of other seizure types in DLP pups.

Cosyntropin did not suppress spasms (Supplementary materials Figure 1). Vigabatrin had a significant effect on spasms only at P5 (P=0.0058) (Figure 7). However, the associated sedation resulted in high mortality rate (50% mortality by P8, 100% mortality by P11).

Figure 7
Vigabatrin transiently suppresses DLP spasms.

Growth, mortality, developmental impairments and underlying neuropathology

There were no significant differences in the weights of DLP and control pups from P3 till P5, even though spasms had already emerged. After P5, DLP pups gained weight at a slower rate than controls (Figure 8). Mortality was highest during the period of spasms (53% till P14) and reached a plateau between P14 – P20. DLP pups had worse performance in OFA, which was sustained even after spasms stopped. Abnormal scores in NG and SRT were also seen in DLP pups in sporadic days especially during the period of spasms (Figure 8).

Figure 8
Abnormalities in developmental milestones in DLP pups.

In the social chamber, DLP pups demonstrated overall fewer attempts to explore the rat chamber as compared to controls, in the presence of either a stranger or familiar rat (Figure 9A). This may suggest indifference to the presence of other rats, preferring to inhabit the middle compartment or may stem from the deficits in exploratory behavior described previously. DLP pups exhibited increased grooming behaviour, which are reminiscent of stereotypies (Figure 9B) (Turner et al, 2001). The increased grooming and decreased numbers of approaches to other rats may indicate autistic symptomatology. In the Barnes maze, DLP did not learn to find the target hole during the trial period whereas control pups showed a rapid learning curve (Figure 9C)

Figure 9
Abnormalities in sociability, grooming behavior, and visuospatial learning in DLP-treated pups with spasms.

The brains of DLP pups showed multifocal pathology involving cortical and subcortical structures including the white matter tracts, most prominent at the right hemisphere and periventricular regions (Figure 10).

Figure 10
Thionin stained coronal sections of a P11 pup with spasms showing showing mostly right hemispheric and periventricular injury that includes 1) thinning of the right hemi-cortex and diffuse damage to the 2) corpus callosum fibers, 3) striatum, 4) periventricular ...


We describe a multiple-hit model of SIS that recapitulates many of the features of human IS as far as phenotype, age specificity, ictal and interictal EEG abnormalities, multifocal pathology, developmental behavioral abnormalities and the occurrence of other seizure types once the spasms have stopped.

In humans, IS are age-specific with a peak onset between 3–7 months (Jeavons et al., 1973). Similarly DLP pups developed spasms between P4–13, classically considered to be equivalent to human neonatal period. However, the drastic improvement in OFA scores between P4–13 pups indicate that this period is equivalent to the developmental period when pups start to develop their ambulatory abilities, a motor milestone that is normally reached during the infantile stage in humans. No spasms were observed beyond P13 but instead we observed other seizure types. Evolution to other epilepsies, including the Lennox-Gastaut syndrome, is well described in human IS (Jeavons et al., 1973; Rantala and Putkonen, 1999; Riikonen, 1982).

Variable ictal discharges were observed with spasms, including electrodecremental-like responses. Similarly, in one study that characterized the ictal correlates of 5042 spasms, 11 ictal abnormalities were observed in association with IS(Kellaway et al., 1979). Classic electrodecremental response was seen in only 37.9 % of spasms. Similar to our model, they also described sharp/slow waves, voltage attenuation and fast activity as ictal correlates. In a proportion of spasms, ictal EEG correlates were not observed in our model. In part this is attributable to movement artifact making the EEG uninterpretable. However, IS in humans can occur without EEG correlates even in the same cluster of spasms where ictal correlates have been identified(Kellaway et al., 1979; Plouin et al., 1993). The reason for this is unknown but it has been suggested that some spasms may have a subcortical generator which can be associated with changes in electrical cerebral activity that do not always propagate to the EEG electrodes(Lado and Moshe, 2002). Although we cannot confirm that DLP pups have hypsarrhythmia as the small size and fragility of their skull limits the number of electrodes that can be placed; the interictal EEG was clearly abnormal suggestive of an epileptic encephalopathy.

In line with human IS, DLP pups showed deficits in the developmental tests in part due to the lesion, resultant neurological deficits and comorbid conditions but possibly also because of the underlying epileptic encephalopathy. In support, the abnormalities in SRT, OFA, NG started at P7, after the onset of spasms, and then partially improved after spasms disappeared. Autism is a neurodevelopment disorder characterized by fundamental core features which include inappropriate social interactions, poor communication skills and ritualistic repetitive behaviors (stereotypies) (Crawley, 2004). Autism is a commonly reported comorbidity in patients with SIS but not in patients with cryptogenic IS, suggesting that the underlying brain lesion or pathology may be more important in the expression of autistic symptomatology than infantile spasms (Riikonen and Amnell, 1981; Saemundsen et al., 2008). To test DLP pups for autistic features we used the social chamber which is an established paradigm to evaluate for abnormal social interactions in rodent models (Crawley, 2004). In this paradigm rodents with autistic features have abnormal approaches to a familiar and-or stranger rat. When tested between P16–19, a period when spasms had resolved but other seizure types were still present, DLP pups had decreased social interactions, as indicated by the reduced number of entries to the rat compartment. The underlying neurological deficits due to the induced brain lesion may contribute to the abnormal social behavior, by impairing the exploratory activity. However, this is also true for the human condition, as only infants with SIS have a greater risk to manifest autistic symptomatology. Pups with IS also demonstrated increased grooming which is thought to be consistent with stereotypies described in autism (Crawley, 2004; Turner et al, 2001). In addition DLP pups performed poorly in tasks requiring learning through visuospatial cues consistent with profound cognitive deficits patterning human mental retardation. Such deficits in visuospatial learning can be at least partially expected by the presence of the right parietal and hippocampal lesion due to the DOX/LPS injections. The extent to which the prior spasms and the underlying epileptic encephalopathy contribute to these cognitive deficits will be best determined when effective antiepileptic therapies are identified in the DLP model.

A limitation of the model is the significant mortality but again 5–30% of the children with IS die and of these deaths 50% are disease-related (Appleton, 2001; Mackay et al., 2004; Rantala and Putkonen, 1999; Riikonen, 1982; Snead et al., 1983). Furthermore, mortality is greater in symptomatic cases(Dulac et al., 1997). At present, it is not possible to differentiate between the impact of spasms and other seizure types versus the structural injury of the brain or co-morbid conditions on these deficits. ACTH was ineffective in treating the spasms in the DLP model, in accordance with clinical reports indicating that human infants with SIS are less likely to respond to ACTH than infants with cryptogenic IS. Vigabatrin resulted in transient suppression of spasms in DLP pups but was also associated with significant mortality, as it caused significant sedation and consequently poor feeding and malnutrition. However, when more effective and safer therapies are identified that suppress the spasms and subsequent seizures in the DLP model, we will be able to determine whether the cognitive deficits and mortality observed in the DLP model can be partially improved by effective antiepileptic therapies, as reported in human patients with IS (Lux et al, 2005).

Several other etiology-based models of infantile spasms have been proposed to model human IS which are reviewed in (Stafstrom, 2009). The corticotropin-releasing hormone (CRH) model was based on the hypothesis that ACTH mediates its effects by suppressing CRH(Brunson et al., 2001). However, intraventricular administration of CRH to neonatal rats results in primarily “limbic” seizures with no reported spasms (Brunson et al., 2001). Another model involves i.p. injections of N-methyl-D-aspartic acid (NMDA) which result in acute, age-specific, expression of spasms that do not last beyond the period of NMDA exposure(Velisek et al., 2007). Prenatal exposure to betamethasone renders the NMDA-induced spasms sensitive to ACTH(Velisek et al., 2007). The tetrodotoxin model, generated by infusions of tetrodotoxin to cortical or hippocampal regions, recapitulates the ictal and interictal EEG patterns in IS, and models cryptogenic or symptomatic IS (Stafstrom, 2009), but the seizures are observed in rats starting at P21(Lee et al., 2008). Deletion of the aristaless-related homeobox (ARX) gene in GABAergic interneurons in mice results in limbic seizures and subsequently spasms in adulthood(Marsh et al., 2009). Knockin mice with expansion of the polyalanine tract of the ARX gene manifest spasm-like myoclonus starting at P7, ictal and interictal EEG patterns, evolution to spontaneous seizures, low anxiety, impaired learning and social interactions (Price et al., 2009). The pharmacosensitivity of the tetrodotoxin and ARX models is not known yet. Administration of baclofen or γ-butyrolactone to the Ts65Dn mouse model of Down syndrome results in brief myoclonic jerks resembling extensor spasms acutely in both infant and adult mice(Cortez et al., 2009). These were significantly reduced by vigabatrin, the rodent ACTH1–24 fragment, ethosuximide, valproic acid and the GABAB antagonist CGP 35348. The existing models include therefore both acute models of spasms (NMDA-induced spasms, baclofen or γ-butyrolactone-induced spasms in Ts65Dn mice) as well as models in which spasms are expressed over a longer period of time (DLP, tetrodotoxin, ARX models). The availability of different acute or chronic etiology-based models of IS with differential sensitivity to available candidate therapies will be important to improve our understanding of this heterogeneous disease, identify common pathogenetic pathways and candidate therapies with either restricted or broader range of indications for the different types of IS, prior to proceeding with the clinical testing.

In this model, spasms are associated with cognitive impairment and autistic features and evolve to other seizure types. One of the advantages is that the spasms occur specifically in the early postnatal period. The mechanisms underlying seizure generation as well as the effects of drugs may be completely different in the developing brain compared to adults(Kaindl et al., 2006; Veliskova et al., 2004). The reliable appearance of spasms for several days will be invaluable in testing drugs with immediate or delayed efficacy in ACTH-refractory SIS as well as identifying other age-specific antiepileptogenic therapies to treat this catastrophic condition.

Supplementary Material


Supplementary Figure 1 ACTH treatment has no effect over spasms in DLP pups.

Synacthène Retard 0.0125 mg/kg/day i.p. was given in DLP pups starting in the afternoon of P4, after the appearance of spasms, till P13 and pups were monitored behaviorally twice daily as described in the methods. They were compared with DLP pups handled similarly and injected with vehicle.




We would like to acknowledge the excellent technical assistance of Mrs. Qianyun Li. This project was supported by NIH NINDS grants NS20253, NS045243, NS58303, NS62947, and grants from the International Rett Syndrome Foundation, PACE, and Heffer Family Foundation. DB was a student at the Summer Undergraduate Research Program of the Albert Einstein College of Medicine. SLM is a recipient of a Martin A and Emily L Fisher Fellowship in Neurology and Pediatrics. This model is patented to the Albert Einstein College of Medicine (AECOM patent # 2080216183).


adrenocorticotropic hormone
aristaless-related homeobox
Fast Fourier Transform
infantile spasms
DLP pups
DOX/LPS/PCPA injected pups
Negative geotaxis
N-methyl-D-aspartic acid
Open field activity
postnatal day
symptomatic infantile spasms
Surface righting time


Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.


  • Appleton RE. West syndrome: long-term prognosis and social aspects. Brain Dev. 2001;23:688–91. [PubMed]
  • Barnes CA, Nadel L, Honig WK. Spatial memory deficit in senescent rats. Can J Psychol. 1980;34:29–39. [PubMed]
  • Blumberg MS, Karlsson KA, Seelke AM, Mohns EJ. The ontogeny of mammalian sleep: a response to Frank and Heller (2003) J Sleep Res. 2005;14:91–8. [PMC free article] [PubMed]
  • Bolivar VJ, Walters SR, Phoenix JL. Assessing autism-like behavior in mice: variations in social interactions among inbred strains. Behav Brain Res. 2007;176:21–6. [PMC free article] [PubMed]
  • Brunson KL, Eghbal-Ahmadi M, Baram TZ. How do the many etiologies of West syndrome lead to excitability and seizures? The corticotropin releasing hormone excess hypothesis. Brain Dev. 2001;23:533–8. [PMC free article] [PubMed]
  • Caplan R, Siddarth P, Mathern G, Vinters H, Curtiss S, Levitt J, Asarnow R, Shields WD. Developmental outcome with and without successful intervention. Int Rev Neurobiol. 2002;49:269–84. [PubMed]
  • Cortez MA, Shen L, Wu Y, Aleem IS, Trepanier CH, Sadeghnia HR, Ashraf A, Kanawaty A, Liu CC, Stewart L, Snead OC., 3rd Infantile Spasms and Down syndrome: A New Animal Model. Pediatr Res. 2009;65(5):499–503. [PubMed]
  • Crawley JN. Designing mouse behavioral tasks relevant to autistic-like behaviors. Ment Retard Dev Disabil Res Rev. 2004;10:248–258. [PubMed]
  • Dulac O, Plouin P, Schlumberger E. Infantile spasms. In: Wyllie E, editor. The treatment of epilepsy: principals and practice. Williams & Wilkins; Baltimore, Maryland: 1997. pp. 540–572.
  • Goh S, Kwiatkowski DJ, Dorer DJ, Thiele EA. Infantile spasms and intellectual outcomes in children with tuberous sclerosis complex. Neurology. 2005;65:235–8. [PubMed]
  • Hrachovy RA, Frost JD., Jr. Infantile epileptic encephalopathy with hypsarrhythmia (infantile spasms/West syndrome) J Clin Neurophysiol. 2003;20:408–25. [PubMed]
  • Jeavons PM, Bower BD, Dimitrakoudi M. Long-term prognosis of 150 cases of “West syndrome” Epilepsia. 1973;14:153–64. [PubMed]
  • Kaindl AM, Asimiadou S, Manthey D, Hagen MV, Turski L, Ikonomidou C. Antiepileptic drugs and the developing brain. Cell Mol Life Sci. 2006;63:399–413. [PubMed]
  • Kellaway P, Hrachovy RA, Frost JD, Jr., Zion T. Precise characterization and quantification of infantile spasms. Ann Neurol. 1979;6:214–8. [PubMed]
  • Lado FA, Moshe SL. Role of subcortical structures in the pathogenesis of infantile spasms: what are possible subcortical mediators? Int Rev Neurobiol. 2002;49:115–40. [PubMed]
  • Lee CL, Frost JD, Jr., Swann JW, Hrachovy RA. A new animal model of infantile spasms with unprovoked persistent seizures. Epilepsia. 2008;49:298–307. [PubMed]
  • Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, O'Callaghan FJ, Verity CM, Osborne JP. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurol. 2005;4:707–12. [PubMed]
  • Mackay MT, Weiss SK, Adams-Webber T, Ashwal S, Stephens D, Ballaban-Gill K, Baram TZ, Duchowny M, Hirtz D, Pellock JM, Sheilds WD, Shinnar S, Wyllie E, Snead OC. Practise parameter: Medical treatment of infantile spasms. Neurology. 2004;62:1668–1681. [PMC free article] [PubMed]
  • Marsh E, Fulp C, Gomez E, Nasrallah I, Minarcik J, Sudi J, Christian SL, Mancini G, Labosky P, Dobyns W, Brooks-Kayal A, Golden JA. Targeted loss of Arx results in a developmental epilepsy mouse model and recapitulates the human phenotype in heterozygous females. Brain. 2009;132:1563–76. [PMC free article] [PubMed]
  • Mikulecka A, Mares P. NMDA receptor antagonists impair motor performance in immature rats. Psychopharmacology (Berl) 2002;162:364–72. [PubMed]
  • Pang Y, Cai Z, Rhodes PG. Disturbance of oligodendrocyte development, hypomyelination and white matter injury in the neonatal rat brain after intracerebral injection of lipopolysaccharide. Brain Res Dev Brain Res. 2003;140:205–14. [PubMed]
  • Plouin P, Dulac O, Jalin C, Chiron C. Twenty-four-hour ambulatory EEG monitoring in infantile spasms. Epilepsia. 1993;34:686–91. [PubMed]
  • Price MG, Yoo JW, Burgess DL, Deng F, Hrachovy RA, Frost JD, Jr., Noebels JL. A triplet repeat expansion genetic mouse model of infantile spasms syndrome, Arx(GCG)10+7, with interneuronopathy, spasms in infancy, persistent seizures, and adult cognitive and behavioral impairment. J Neurosci. 2009;29:8752–63. [PMC free article] [PubMed]
  • Primec ZR, Stare J, Neubauer D. The risk of lower mental outcome in infantile spasms increases after three weeks of hypsarrhythmia duration. Epilepsia. 2006;47:2202–5. [PubMed]
  • Rantala H, Putkonen T. Occurrence, outcome, and prognostic factors of infantile spasms and Lennox-Gastaut syndrome. Epilepsia. 1999;40:286–9. [PubMed]
  • Rattray M, Baldessari S, Gobbi M, Mennini T, Samanin R, Bendotti C. p-Chlorphenylalanine changes serotonin transporter mRNA levels and expression of the gene product. J Neurochem. 1996;67:463–72. [PubMed]
  • Riikonen R. A long-term follow-up study of 214 children with the syndrome of infantile spasms. Neuropediatrics. 1982;13:14–23. [PubMed]
  • Riikonen R, Amnell G. Psychiatric disorders in children with earlier infantile spasms. Dev Med Child Neurol. 1981;23:747–60. [PubMed]
  • Saemundsen E, Ludvigsson P, Rafnsson V. Risk of autism spectrum disorders after infantile spasms: a population-based study nested in a cohort with seizures in the first year of life. Epilepsia. 2008;49:1865–70. [PubMed]
  • Siegal T, Melamed E, Sandbank U, Catane R. Early and delayed neurotoxicity of mitoxantrone and doxorubicin following subarachnoid injection. J Neurooncol. 1988;6:135–40. [PubMed]
  • Silverstein F, Johnston MV. Cerebrospinal fluid monoamine metabolites in patients with infantile spasms. Neurology. 1984;34:102–5. [PubMed]
  • Snead OC, 3rd, Benton JW, Myers GJ. ACTH and prednisone in childhood seizure disorders. Neurology. 1983;33:966–70. [PubMed]
  • Stafstrom CE, Moshe SL, Swann JW, Nehlig A, Jacobs MP, Schwartzkroin PA. Models of pediatric epilepsies: strategies and opportunities. Epilepsia. 2006;47:1407–14. [PubMed]
  • Stafstrom CE. Infantile spasms: a critical review of emerging animal models. Epilepsy Curr. 2009;9:75–81. [PMC free article] [PubMed]
  • Turner CA, Presti MF, Newman HA, Bugenhagen P, Crnic L, Lewis MH. Spontaneous stereotypy in an animal model of Down syndrome: Ts65Dn Mice. Behavior Genetics. 2001;31:393–400. [PubMed]
  • Uhler M, Herbert E. Complete amino acid sequence of mouse pro opiomelanocortin derived from the nucleotide sequence of pro-opiomelanocortin cDNA. J Biol Chem. 1983;258:257–61. [PubMed]
  • Velisek L, Jehle K, Asche S, Veliskova J. Model of infantile spasms induced by N-methyl-D-aspartic acid in prenatally impaired brain. Ann Neurol. 2007;61:109–19. [PubMed]
  • Veliskova J, Claudio OI, Galanopoulou AS, Lado FA, Ravizza T, Velisek L, Moshe SL. Seizures in the developing brain. Epilepsia. 2004;45(Suppl 8):6–12. [PubMed]
  • Watanabe K. West syndrome: etiological and prognostic aspects. Brain Dev. 1998;20:1–8. [PubMed]